Banque Cantonale Vaudoise Sells 1,204 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Banque Cantonale Vaudoise trimmed its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 24.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,730 shares of the company’s stock after selling 1,204 shares during the quarter. Banque Cantonale Vaudoise owned about 0.09% of Invesco Biotechnology & Genome ETF worth $260,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV grew its position in Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after acquiring an additional 299 shares in the last quarter. Massachusetts Wealth Management grew its position in Invesco Biotechnology & Genome ETF by 7.3% in the third quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after acquiring an additional 1,240 shares in the last quarter. Carnegie Investment Counsel purchased a new position in Invesco Biotechnology & Genome ETF in the third quarter worth about $204,000. Cetera Investment Advisers grew its position in Invesco Biotechnology & Genome ETF by 2.1% in the second quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock worth $1,808,000 after acquiring an additional 561 shares in the last quarter. Finally, One Capital Management LLC grew its position in Invesco Biotechnology & Genome ETF by 31.9% in the second quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock worth $1,646,000 after acquiring an additional 6,137 shares in the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of NYSEARCA:PBE opened at $69.56 on Friday. Invesco Biotechnology & Genome ETF has a 1 year low of $56.21 and a 1 year high of $72.84. The business has a 50 day simple moving average of $69.31 and a two-hundred day simple moving average of $67.81. The firm has a market capitalization of $281.02 million, a PE ratio of 17.12 and a beta of 0.88.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.